News

Under the terms of the agreement, Abbott will perform scale-up and GMP manufacturing of TRX4 for use in clinical trials, as well as supply commercial-grade material to support

The first phase II clinical compound, VTP-201227, has a novel mechanism of action and is being developed as a topical agent for the treatment of psoriasis with potential

In order to enter and infect cells HIV must bind to either the CXCR4 or CCR5 receptor, AMD070 is designed to stop the virus from entering the cells

YSPSL was developed by Wyeth and was acquired by Y’s Therapeutics from an undisclosed California biotechnology company in June 2005, providing Y’s with an exclusive, worldwide license from

Under the terms of the deal, Valeant will pay $113.5 million in cash upon closing, and subsequent milestone payments of up to approximately $22.5 million. Valeant will also

At closing, Neurobiological Technologies Inc (NTI) received $20 million and will receive an additional $13 million, payable in installments through January 2007. Celtic Pharma and NTI will collaborate

Alza originally submitted the application for licensure of Ionsys to the FDA in September 2003, but received an approvable letter from the FDA in mid-2004 informing the company

The first collaboration will focus upon a group of compounds that target the NMDA 2B receptor and will be developed for the treatment of chronic pain and other

Myasthenia gravis (MG) is a debilitating, chronic autoimmune neuromuscular disease in which the body produces auto-antibodies that prevent the nerves from sending messages to the muscles. The randomized,